Jack Allen
Stock Analyst at Baird
(1.03)
# 3,917
Out of 5,093 analysts
42
Total ratings
41.18%
Success rate
-11.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $57.04 | -22.86% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $10.72 | +497.01% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $5.31 | +125.99% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.05 | +280.95% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.42 | +533.80% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $12.99 | +207.93% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $70.84 | +49.63% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $9.30 | +93.55% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $11.04 | +1,530.43% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.18 | +266.97% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $36.54 | +129.89% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.74 | +187.36% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.57 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.29 | +109.79% | 1 | Oct 7, 2021 |
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $57.04
Upside: -22.86%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $10.72
Upside: +497.01%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $5.31
Upside: +125.99%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.05
Upside: +280.95%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.42
Upside: +533.80%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $12.99
Upside: +207.93%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $70.84
Upside: +49.63%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $9.30
Upside: +93.55%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $11.04
Upside: +1,530.43%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.18
Upside: +266.97%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $36.54
Upside: +129.89%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.74
Upside: +187.36%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.57
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.29
Upside: +109.79%